CryoLife (CRY) Cash Flow Statement

Click line-items for a historical chart and %

Net income	7.88M
Depreciation and amortization	6.25M
Deferred income taxes
Non-cash compensation	4.62M
Gain on valuation of derivative
Other non-cash adjustments to income	5.6M
Receivables
Deferred preservation costs and inventories	-5.74M
Prepaid expenses and other assets	-46K
Accounts payable, accrued expenses, and other liabilities	304K
Net cash flows provided by operating activities
Acquisition of Cardiogenesis, net of cash acquired	-91.15M
Capital expenditures	-3.51M
Purchases of restricted securities and investments
Other	-12K
Net cash flows used in investing activities
Principal payments on debt
Proceeds from financing of insurance policies	75M
Principal payments on short-term notes payable	-1.41M
Proceeds from exercise of stock options and issuance of common stock	2.12M
Repurchase of common stock
Other	-28K
Net cash flows used in financing activities
(Decrease) increase in cash and cash equivalents	16.54M
Effect of exchange rate changes on cash	-418K
Cash and cash equivalents, beginning of period	37.59M
Cash and cash equivalents, end of period	54.13M

Entities mentioned with CRY

View All Entities